Inclisiran With LLT Reduces LDL-C in Hypercholesterolemia Without Inducing Muscle Pain
September 9th 2025In combination with lipid-lowering therapy, inclisiran allowed patients with hypercholesterolemia to reach their low-density lipoprotein cholesterol (LDL-C) goals without associated muscle-related adverse events.
ESC 2023 Highlights: Insights on ALONE-AF and AQUATIC Trials
Host Craig Beavers sits down with Lorenz van der Linden, a Belgian pharmacist, to dive deep into 2 groundbreaking trials from the European Society of Cardiology (ESC) 2025 Congress.
Full Phase 3 Results Indicate Reduced Blood Pressure With Baxdrostat in Hypertension
September 8th 2025The trial results, which showed baxdrostat significantly reduced mean seated systolic blood pressure in uncontrolled hypertension, were presented at the 2025 European Society of Cardiology Congress.
COMPASS Trial Results: Rivaroxaban Plus Aspirin Protects Against Heart Attack, Stroke
August 28th 2017In this clip, Deepak Bhatt, MD, discusses the results of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial, presented at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.